This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Procalcitonin as a Marker of Bacterial Pneumonia

This study has been completed.
Information provided by:
Aarhus University Hospital Skejby Identifier:
First received: December 22, 2006
Last updated: May 22, 2008
Last verified: May 2008

Objective: To evaluate PCT as a marker of bacterial community acquired pneumonia in a Danish Hospital setting. To test if it is possible to reduce the use of antibiotics and the length of stay in hospital, and the willingness of the clinicians to take this new marker under advisement in their choice of treatment.

The study is a randomised, controlled intervention study. All adult patients admitted to the Department of Infectious Disease at Skejby hospital suspected of a lower respiratory tract infection (e.g. CAP, acute exacerbation of COPD and bronchitis) are eligible for inclusion. Patients are randomised to have either PCT guided treatment or standard care, in which case the doctor will not learn the PCT test result. In the PCT group the antibiotic treatment will be based on serum PCT as follows: If PCT is less than 0.25 µg/L antibiotic treatment is discouraged; if PCT is greater than 0.25 µg/L antibiotic treatment is encouraged and if PCT is greater than 0.5 µg/L antibiotic treatment is strongly encouraged. The treating doctor is allowed to overrule the treatment guidelines. The control group will receive antibiotics according to usual practice.

The primary endpoints are antibiotic use and length of stay in hospital. Secondary endpoint is the proportion of patients where the treating doctor chooses to disregard the guidelines.

Condition Intervention
Pneumonia Bronchitis COPD Behavioral: No antibiotics if se-procalcitonin is below stated limit

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic

Resource links provided by NLM:

Further study details as provided by Aarhus University Hospital Skejby:

Primary Outcome Measures:
  • Antibiotic use
  • Length of stay in hospital

Secondary Outcome Measures:
  • The proportion of patients where the doctor chooses to disregard treatment guidelines

Enrollment: 223
Study Start Date: June 2006
Study Completion Date: August 2007
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • suspected lower respiratory tract infection
  • must be able to give consent

Exclusion Criteria:

  • age under 18 years
  • not able to give consent
  • admitted not primarily because of the respiratory tract infection
  • hospital acquired infections
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415753

Department of Infectious Diseases, Skejby Hospital
Aarhus N, Denmark, 8200
Departement of Medicin, Silkeborg Hospital
Silkeborg, Denmark, 8600
Sponsors and Collaborators
Aarhus University Hospital Skejby
Study Chair: Finn T Black, Professor Aarhus Universityhospital
Principal Investigator: Kristina B Kristoffersen Aarhus University Hospital Skejby
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Skejby Hospital Identifier: NCT00415753     History of Changes
Other Study ID Numbers: 271-05-0765
Study First Received: December 22, 2006
Last Updated: May 22, 2008

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Bronchial Diseases
Lung Diseases, Obstructive
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017